Thymosin alpha1 inhibits mammary carcinogenesis in Fisher rats.
Moody. Terry W TW; Tuthill. Cynthia C; Badamchian. Mahnaz M; Goldstein. Allan L AL
Key Findings
- Daily 10 µg subcutaneous thymosin‑alpha‑1 reduced mammary tumor incidence in NMU‑treated Fisher rats
- Treated rats showed longer survival compared to controls
- Talpha1 increased blood white‑cell counts, indicating immune stimulation
Practical Outcomes
- The results hint that thymosin‑alpha‑1 might support the immune system in ways that could lower cancer risk, but the evidence is limited to rats and a specific chemical model. Biohackers should view this as an early, non‑clinical signal and not a ready‑to‑use protocol for humans; more human research is needed before considering supplementation.
Summary
In a rat study, giving a tiny daily dose of the peptide thymosin‑alpha‑1 under the skin lowered the number of breast cancers that developed after a chemical trigger and helped the animals live longer, likely by boosting their white blood cells.
Abstract
The effects of thymosin alpha1 (Talpha1) on mammary carcinogenesis was investigated in Fisher rats. Mammary carcinomas were observed 3 months after N-nitrosomethylurea (NMU) injection (10mg, i.p.) into Fisher rats. Daily administration of Talpha1 (10 microg, s.c.) reduced mammary carcinoma incidence and prolonged survival time. Animals treated with exogenous Talpha1 had a significantly greater blood white cell density than control Fisher rats. These results suggest that Talpha1 prevents mammary carcinoma incidence as a result of stimulation of the immune system.
Study Information
pubmed
2002
10.1016/s0196-9781(02)00025-6